PARTICIPATION IN CLINICAL TRIALS
|Clinical trials||Clinical Phase of Trial (I-IV)||Role in Trial||Indication of Trial|
|RE-LY||Phase III||Sub investigator||ATRIAL FIBRRILATION|
|AVERROES||Phase III||Sub investigator||ATRIAL FIBRRILATION|
|VITATOPS||Phase III||Sub investigator||STROKE|
|ARISTOTLE||Phase III||Sub investigator||ATRIAL FIBRRILATION|
|ENGAGE AF-TIMI 48||Phase III||Sub investigator||ATRIAL FIBRRILATION|
|ADOPT||Phase III||Sub investigator||THROMBO-PROPHYLAXIS|
|CL3-16257-068||Phase III||Sub investigator||STABLE ANGINA|
PARTICIPATION IN CLINICAL TRIAL
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study).
A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation (ARISTOTLE).
Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial (AVERROES).
VITATOPS - A Study of VITAmins TO Prevent Stroke
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris: A 6-week, randomised, double-blind, parallel-group, international, multicentre study (CL3-16257-068)
A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization (ADOPT).